Donald Trump knocked yet another industry in his press conference Wednesday, but this time it wasn’t manufacturers or car makers. It was health care. And shares of U.S. pharmaceutical companies promptly fell, dropping by an average range of about 3% to 5%. “We’ve got to get our drug industry back,”
I can safely say that, from my 35 years in the financial markets, to be consistently successful at investing, one must put prudence over popularity. Human nature as it is, investors often find it difficult to take unpopular actions. My motivation in writing this column is to nudge you
Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely to succeed. Obamacare in its current form is the walking dead. Trump has said that he will replace Obamacare with something better. In his speeches, Trump outlined certain key points
(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers. ) JAPAN STUNS WITH NEGATIVE INTEREST RATES, RUSSIA CLARIFIES ON OIL, AND GDP RELEASE January 29, 2016 This is what you need to know today. Japan
One of the rumored suitors of SNN has been MDT. MDT just bought COV and is now likely out of the race to buy SNN. There are still other suitors of SNN such as SYK and JNJ, but the stock is likely to drift lower unless an immediate bid appears.
It is official: India is siding with poor cancer patients over profits for multinational drug giants. The Supreme Court of India has rejected a plea by Swiss pharma giant Novartis that ends the seven-year legal battle to restrict Indian companies from copying blood cancer drug Glivec. Novartis had filed a plea with the Supreme
(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers.) THE RALLY IS LONG IN THE TOOTH January 25, 2013 The stock market rally is long in the tooth. Our long time subscribers know
Nine jurors in the Federal Court of the Northern District of California, handed Apple a big victory against Samsung, awarding Apple $1.05 billion in damages, finding all seven of Apple’s patents valid, finding Samsung infringed six of Apple’s patents, and finding Apple not to have infringed any of Samsung’s five patents. The
A popular axiom among long-only investors is to “buy low sell high.” For those investors who are equally interested in making money from both markets going up and markets going down, the parallel axiom is, “short-sell high and buy-to-cover low.” In the short-term, the stock market is overbought, and it
NUVA stock has been down today on rumors that JNJ (Johnson & Johnson) will announce a lateral fusion device in the post earnings conference call. JNJ web site shows that the head of its device business will be on the call indicating there may be some truth to the rumor.